Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Collaboration › Details

Argenx–Morgan Stanley: investor conference, 202109 supply service Argenx presents at Morgan Stanley 19th Annual Global Healthcare Conference 2021

 

Period Period 2021-09-10
Organisations Partner, 1st Argenx SE (Euronext + Nasdaq: ARGX)
  Group Argenx (Argen-X) (Group)
  Partner, 2nd Morgan Stanley & Co. LLC
  Group Morgan Stanley (Group)
Products Product Morgan Stanley Global Healthcare Conference 2021 DIGITAL
  Product 2 therapeutic antibody
     

Argenx SE. (9/3/21). "Press Release: Argenx to Present at Upcoming Investor Conferences". Breda.

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:

> KBC Life Sciences & Biotech Virtual Conference. Management will participate in investor meetings on Tuesday, September 7, 2021.

> Morgan Stanley Global Healthcare Conference. Fireside chat on Friday, September 10, 2021 at 4:15 p.m. ET.

> BofA Global Healthcare Conference. Fireside chat on Thursday, September 16, 2021 at 4:45 p.m. BST.

> SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event. Management will participate in investor meetings on Wednesday, September 22, 2021.

Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.


About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn.


For further information, please contact:

Media:

Kelsey Kirk
kkirk@argenx.com

Joke Comijn (EU)
jcomijn@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com

   
Record changed: 2021-09-12

Advertisement

Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px

More documents for Argenx (Argen-X) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px




» top